Drugs / viral specific T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02532452 | Sep 2015 → Dec 2026 expected | disease arising from reactivation of latent virus | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | viral specific T-cells | “viral specific T-cells (VSTs) with specificity for Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (ADV), BK virus (BKV), and JC Virus.” NCT02532452 ↗ |
| Known as | VSTs | “use the blood to generate viral specific T-cells (VSTs) with specificity for Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (ADV), BK virus (BKV), and JC Virus.” NCT02532452 ↗ |
| Modality | Cell therapy | “Cellular therapy using T cells directed against BKPyV is an emerging therapy” PMID 33216887 ↗ Nov 2020 |